Brief: Acumen Pharmaceuticals Presents Studies Showing Utility Of Ptau217 Assay In Screening For Phase 2 Alzheimer’S Disease Trial And Validates Sabirnetug Oligomer-Selectivity, At The Alzheimer’S Association International Conference (Aaic) 2025
28/07/2025 13:04
July 28 (Reuters) - Acumen Pharmaceuticals Inc ABOS.O: ACUMEN PHARMACEUTICALS PRESENTS STUDIES SHOWING THE UTILITY OF A PTAU217 ASSAY IN SCREENING FOR A PHASE 2 ALZHEIMER’S DISEASE TRIAL AND VALIDATES SABIRNETUG OLIGOMER-SELECTIVITY, AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2025 Source text: ID:nGNX6JRw9q Further company coverage: ABOS.O (Reporting by Anshi Sancheti) ((Anshi.Sancheti@thomsonreuters.com;))